Biotech startups in India are entering the global stage.

Pandorum Technologies has raised $18M (~₹150 Cr) in a Series B round led by Proton's Corporate, with participation from Galentic Pharma and Ashish Kacholia.

Founded by Tuhin Bhowmick and Arun Chandru, the Bengaluru-based startup is building regenerative medicine and exosome-based therapies for complex diseases.

The funds will be used to advance clinical development, scale global manufacturing, and expand into markets like the US, Japan, and the Middle East.

: Key Insights

• Focus on ocular diseases like Stevens–Johnson Syndrome and Neurotrophic Keratitis
• Lead program Kuragenx has received US FDA Orphan Drug Designation
• One of India’s early deep-tech biotech startups

Why this matters:

Indian biotech startups are moving from research → global clinical impact.

: Can India build globally competitive biotech companies in deep-tech healthcare?